ELMD
Electromed, Inc.
ELMD offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over ELMD overall, supported by stronger modeled upside and stronger fundamentals.
ELMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
ELMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ELMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $24.97 | — |
| Cheap | 25x | $34.57 | +38% |
| Fair | 31x | $43.15 | +73% |
| Expensive | 44x | $60.28 | +141% |
Historical ranges are pointers, not guarantees.
ELMD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ELMD Forward outlook
There aren't enough analyst estimates for ELMD to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ELMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.37 | +46% |
| Q2 2026 | $1.30 | +53% |
| Q1 2026 | $1.18 | +49% |
| Q4 2025 | $1.04 | +39% |
| Q3 2025 | $0.94 | +31% |
| Q2 2025 | $0.85 | +47% |
| Q1 2025 | $0.79 | +58% |
| Q4 2024 | $0.75 | +67% |
ELMD's earnings per share have climbed steadily: $1.37 over the past year, up 46% from the year before, and higher year over year for 15 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ELMD on earnings, with stronger typical year-over-year growth.
ELMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | +11% |
| Q2 2026 | $19.4M | +12% |
| Q1 2026 | $18.6M | +18% |
| Q4 2025 | $18.9M | +16% |
| Q3 2025 | $16.9M | +15% |
| Q2 2025 | $17.4M | +17% |
| Q1 2025 | $15.7M | +13% |
| Q4 2024 | $16.3M | +19% |
ELMD's revenue has grown year over year every quarter since late 2020: $19M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 20% | +2.2 points |
| Q1 2026 | 20% | +6.6 points |
| Q4 2025 | 19% | +3.5 points |
| Q3 2025 | 16% | +2.6 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 14% | +0.4 points |
| Q4 2024 | 16% | -0.9 points |
ELMD's operating margin was 19% last quarter, up 2.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ELMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ELMD on profitability, with a higher operating margin.
ELMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $208K | +$291K |
| Q2 2026 | $2.8M | -25% |
| Q1 2026 | $3.3M | +49% |
| Q4 2025 | $2.4M | -18% |
| Q3 2025 | -$83K | -104% |
| Q2 2025 | $3.7M | -17% |
| Q1 2025 | $2.2M | +76% |
| Q4 2024 | $2.9M | -14% |
ELMD generated $9M in free cash flow over the past year, about the same as the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ELMD on cash flow, with more consistent year-over-year improvement.
ELMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +72.8K shares |
| 1 year | +0.9% | +79.7K shares |
| 3 years | -0.2% | -21.4K shares |
| 5 years | -1.4% | -123K shares |
| Available history | 0% | +2.3K shares |
ELMD has 9M diluted shares, up 0.9% from a year ago, despite $7M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | — |
| Q1 2026 | $152,000 |
| Q4 2025 | $2.8M |
| Q3 2025 | $1M |
| Q2 2025 | $3.7M |
| Q1 2025 | $1.8M |
| Q4 2024 | — |
ELMD spent $7M buying back its own shares over the past year, up 12% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ELMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ELMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.7x | Net Cash |
ELMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ELMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.8 | Neutral |
| Stochastic | 7.0 | Oversold |
ELMD's weekly RSI is 36 (neutral) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ELMD PE vs Healthcare Sector
| Metric | ELMD | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 1 | 29 | 28 pts below |
ELMD has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ELMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.1 | 7.8% below |
| 20 week MA | $33.2 | 25% below |
| 50 week MA | $30.7 | 19% below |
| 100 week MA | $27.5 | 9.3% below |
| 200 week MA | $20.9 | 20% above |
ELMD has fallen below most of its moving averages, though it's still 20% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ELMD on trend strength, trading above more of its moving averages.
ELMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.57 | $9.99 | +17% |
| 2021 | $9.99 | $12.7 | +27% |
| 2022 | $12.7 | $9.89 | -22% |
| 2023 | $9.89 | $10.9 | +10% |
| 2024 | $10.9 | $29.2 | +168% |
| 2025 | $29.2 | $28.5 | -2.5% |
| 2026 YTD | $28.5 | $25.0 | -12% |
ELMD has finished higher in four of the last six years. It's down 12% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ELMD on returns for 2026, with the stronger performance.